WAG
PCVX icon

Windsor Advisory Group’s Vaxcyte PCVX Stock Holding History

Windsor Advisory Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-39,223
Closed -$3.21M – 64
2024
Q4 		$3.21M Buy
39,223
+16,479
+72% +$1.64M 3.73% 4
2024
Q3 		$2.6M Buy
+22,744
New +$2.05M 2.93% 4

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Windsor Advisory Group's PCVX Position: Q1 2025 in Review

Windsor Advisory Group sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 39,223 shares — an estimated $3.21M sold.

Windsor Advisory Group first reported a position in PCVX in Q3 2024 and held it in 2 quarters. The position peaked at $3.21M in Q4 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Windsor Advisory Group reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Windsor Advisory Group sold 39,223 Vaxcyte shares in Q1 2025, an estimated $3.21M.
  • Windsor Advisory Group first reported a position in Vaxcyte in Q3 2024 and held it in 2 quarters.
  • Windsor Advisory Group's Vaxcyte position peaked at $3.21M in Q4 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Windsor Advisory Group's 13F filing for Q1 2025, filed 15 May 2025.